Purpose: To determine the frequency and appearance of radiation-induced liver disease on PET/CT in patients undergoing serial imaging during neoadjuvant chemoradiation of distal esophageal cancer. Materials and methods: In this IRB-approved, HIPAAcompliant retrospective analysis, we identified 112 patients with distal esophageal cancer treated by neoadjuvant chemoradiation who had serial PET/CT imaging available for review. Two readers reviewed all studies in consensus and recorded those cases where new foci of visually detectable increased FDG avidity appeared in the liver during therapy. The etiology of such foci was determined from corresponding findings at CT or MRI, by hepatic biopsy during surgery, by characteristic evolution on postoperative imaging, or by a combination of these methods. Results: New foci of FDG avidity developed in the liver during neoadjuvant therapy in 10 of 112 (9%) patients, of whom nine (8%) were determined to have radiationinduced liver disease based on further imaging and/or biopsy and one of whom had developed interval metastatic disease based on biopsy. In the cases of radiation-induced liver disease, the abnormal foci were found only in the caudate and left hepatic lobes, near the primary tumor, while the patient who developed interval metastatic disease had involvement of the inferior right hepatic lobe, remote from the radiation therapy field. Conclusion: New foci of increased FDG avidity are commonly seen in the caudate and left hepatic lobes of the liver during neoadjuvant chemoradiation of distal esophageal cancer, and these findings generally reflect radiation-induced liver disease rather than metastatic disease.
An estimated 17990 new cases of esophageal cancer will be diagnosed in the United States during 2013, with 15210 deaths due to the disease [1] . Neoadjuvant chemoradiation, in appropriately selected patients, seems to improve survival and reduce local recurrence [2] [3] [4] [5] [6] [7] [8] and has become an increasingly common management strategy. In parallel with this therapeutic advance, PET/CT has become increasingly used as valuable imaging tools, both for baseline staging and for evaluation of treatment response [7] [8] [9] [10] [11] [12] [13] [14] . However, it is known that radiation-induced liver disease can be a complication of radiotherapy, and one small study (n = 26) suggested that it may cause potentially confusing increased FDG avidity in the liver [13] . Therefore, we undertook this study to determine the frequency and appearance of radiation-induced liver disease on PET/CT in patients undergoing serial imaging during neoadjuvant chemoradiation of distal esophageal cancer.
Materials and methods

Subjects
This was a retrospective single institutional study approved by our Institutional Review Board with waiver of the requirement for informed consent. The study was compliant with the Health Insurance Portability and Accountability Act. We performed a search of our institutional multidisciniplary esophageal cancer conference patient database, and identified all patients (n = 112) between 2006 and 2013 who met the following inclusion criteria:
1. Pathologically proven distal esophageal cancer. 2. Baseline and post-neoadjuvant chemoradiation PET/ CT imaging available on our institutional picture archiving and communication system (PACS-Impax; Agfa, Mortsel, Belgium). All except one patient with post-treatment PET/CT, studies were performed within 4 to 8 weeks after cessation of chemoradiation. One patient had post-treatment PET/CT 5 months after completion of therapy. 3. Documentation of radiotherapy and dose available in our electronic medical record (EPIC Hyperspace 2010). Details were recorded by the principal investigator (-).
The final study population (n = 112) consisted of 93 men and 19 women, with a mean age of 57 years (range 28-81). Histological diagnoses were esophageal adenocarcinoma (n = 97), squamous cell carcinoma (n = 21), and cancer not otherwise specified (n = 4).
Radiotherapy technique
All patients who received their radiotherapy at our institution (n = 20) were treated on an integrated CT and intensity modulated radiation therapy (IMRT) device (Tomotherapy TomoHD; Accuray, Madison, WI, USA). Patients initially underwent a volumetric planning CT examination to define the gross tumor volume, clinical target volume, and planning target volume. The gross tumor volume encompasses the primary tumor and clinically positive lymph nodes seen on the baseline/ pretreatment radiologic examinations, including PET/ CT with all lesions exhibiting an FDG avidity of maximum standard uptake values (SUV max ) >3. Other modalities included in determining the gross tumor volume include diagnostic and treatment planning CT, fluoroscopic studies, endoscopic ultrasound, and esophagogastroduodenoscopy. The clinical tumor volume includes the gross tumor volume plus a 0.5-1 cm radial margin as well as a 3-5 cm craniocaudal margin. The extended margins of the clinical tumor volume account for microscopic tumor extension. Also included in the clinical tumor volume is a 1.0 cm margin for any grossly involved lymph nodes and the celiac and peri-gastric nodes. The planning tumor volume adds an additional 1.0 cm to the clinical tumor volume in all directions. The volumetric planning CT was performed in either the supine or prone positions in an immobilization device, with patients in the actual treatment position. Contiguous 3-mm-thick axial CT slices through the tumor as well as any involved nodal groups were acquired. The remaining regions of disease are also scanned at 8-10 mm slice thickness extending as inferiorly as the third lumbar vertebral body in the cases of distal esophageal cancer. Intravenous iodinated contrast was only administered, if no prior contrast-enhanced CT was performed for delineation of major blood vessels. Positive enteric contrast was administered in all cases 1 hour before scanning to opacify the stomach, and oral paste was given at the time of simulation to coat the esophagus. All patients were treated with the planning tumor volume field and dosages ranged from 41.4 to 50.4 Gy in 1.8 Gy fractions. Patients treated at other facilities (n = 92) extended the total range of dosage from 45 Gy to 64 Gy, with 1.8 Gy fractions.
PET/CT technique
A total of 109 PET/CT scans were performed at our institution (42 baseline and 67 post-treatment studies) on an integrated PET/CT scanner (GEMINI TF, Phillips Medical Systems, Cleveland, OH, USA). Prior to scanning, patients fasted for at least 6 h with no caffeine, alcohol, or nicotine products 24 h prior to examination. All patients drank at least eight glasses of water and abstained from heavy exercise and/or muscular activity the day before the examination. Blood glucose levels were determined utilizing a point-of-care glucometer approximately 4 h before examination, and in all cases, blood glucose levels were less than 200 g/dL. Patients were injected with a mean of 12 mCi (range 10-14 mCi) of 18 F-radioactively-labeled FDG. After injection, the patients rested for 60 min in quiet conditions and drank 1000 mL of water 20 min before imaging time. Immediately before the PET examination, patients emptied their bladder.
Non-contrast CT scanning was then performed from the skull base through the thighs (40-90 mAs, 120 kVp, 5 mm thick slices, 5 mm increments) on the integrated multidetector device. PET images were acquired immediately following the CT scan, which were performed from the skull base to the thighs in 60-120 s per bed position depending upon the patient's weight. Reconstruction of the PET images utilized the standard vendorprovided reconstruction algorithms that employed Lineof-Response Row-Action Maximum Likelihood Algorithm (LOR-RAMLA). The CT component of the examination was utilized for attenuation correction. The PET data was corrected for dead-time losses, scatter, and random events through the manufacturer's software package.
An additional 115 PET/CT examinations (70 baseline and 45 post-treatment studies) utilized in our analysis were performed at outside/referring medical institutions for a total of 224. All PET/CTs except one of these were performed on integrated machines. Fasting periods, blood glucose level determination, and 18 F-FDG doses were performed under the general accepted guidelines of the referring medical institutions.
PET/CT image interpretation
All PET/CT images were reviewed on our institutional PACS by two board certified radiologists (-, -). By consensus, readers determined if foci of increased FDG avidity were present in the liver on baseline and postradiation scans. A focus of increased hepatic FDG avidity was defined as a region of increased FDG uptake in the liver that was visually detectable over the normal mottled activity of the background liver. For those abnormal studies which were performed at our institution, 3D region of interest cursors was used to measure SUV max within the detected abnormalities where subjectively increased FDG avidity was evident. Determination of background hepatic FDG avidity utilized a SUV max mean of 5 separate random hepatic parenchymal locations measured with 3D region of interest cursors.
Reference standard
In the patients who were identified as having new foci of hepatic FDG avidity developing on post-chemoradiation PET/CT scanning, all available clinical, surgical, pathological, and radiological records were examined to establish the underlying diagnosis. Typical geographic regions of hypoattenuation with straight margins on the CT for attenuation correlation (CTAC; performed in conjunction with the PET) were considered diagnostic of radiation-induced liver disease [14] [15] [16] [17] . Contrast-enhanced CT scan criteria for confirmation of radiationinduced liver disease included regions with well-demarcated angular/polygonal margins exhibiting arterial and portal venous hypoenhancement with delayed phase hyperenhancement that corresponded to the intrahepatic FDG-avid foci [14] [15] [16] [17] [18] [19] . In patients with short interval follow up MRI, sharply delineated polygonal regions of early and persistent enhancement with low T1 and high T2 signal that mapped to the intrahepatic FDG-avid foci were used to diagnose radiation-induced liver disease [15-17, 19, 20] . Lack of mass effect on all three modalities further indicated radiation-induced liver disease [21, 22] . Resolution of the PET, CT, and MRI abnormalities on subsequent examinations also qualified as diagnostic of radiation-induced liver disease. Patients were considered to have metastatic disease, if there was interval increasing growth and/or persistent FDG avidity on subsequent examinations as well as surgical pathology. 
Results
None of the 112 patients had foci of increased FDG uptake visible in the liver on baseline PET/CT. New foci of increased hepatic FDG avidity were seen in 10 of the 112 patients (9%) on the post-treatment PET/CT examinations, 6 (6%) of which had corresponding regions of faint hypoattenuation on the corresponding non-contrast CT. Benignity of the FDG-avid foci was confirmed in 9 (8%) of patients with 1 (1%) patient determined to have metastatic disease (Table 1) . The mean SUV max of the FDG-avid foci determined to be radiation-induced liver was 5.7 (range 5.0-8.8). A representative case is illustrated in Figure 1 . The patient with confirmed hepatic metastasis (Fig. 2) exhibited a lesion SUV max of 12.8.
Discussion
Common sites of metastatic spread in esophageal cancer include the abdominal lymph nodes, liver, and lungs [10, [23] [24] [25] [26] . In one study, it was shown that up to 35 % of patients with esophageal cancer will develop liver metastases [29] . In addition to metastatic disease, the liver is also particularly prone to radiation-induced liver disease during radiotherapy of distal esophageal cancer, due to the close proximity of the left lobe which is accordingly included in the standard radiation field [27] [28] [29] . Given that serial PET/CT is increasingly performed during neoadjuvant chemoradiation of esophageal cancer and that both metastases and radiation-induced liver disease may manifest as increased foci of FDG avidity at PET scanning, our study provides important results that address how these two entities might be distinguished. First, we found that new foci of hepatic FDG avidity developing during neoadjuvant chemoradiation of esophageal cancer are usually due to radiation-induced liver disease. Increased FDG avidity in radiation-induced liver disease results from inflammation caused by radiation with increased FDG uptake by active leukocytes [30] . This simple observational result is statistically reassuring, and likely reflects the low likelihood of metastases developing during neoadjuvant chemoradiation. Second, while based on small numbers, we found that the location of the new foci of FDG avidity may be important. All the foci due to radiation-induced liver disease developed in the left and caudate lobes (Fig. 1) , within the presumed radiation field, while the sole case of metastatic disease developed in the inferior right hepatic lobe, remote from the primary tumor and radiation field (Fig. 2) . In a broader context, our study expands the existing literature on ''pseudoprogression'', that is, the development of new findings in cancer patients may falsely indicate disease progression. A study similar to ours evaluating new FDG-avid osseous lesions in patients treated with radiation for pelvic malignancy demonstrated that the lesions were more likely to be insufficiency fractures from osteoradionecrosis than actual disease progression [31] . Perhaps the best known examples of pseudoprogression are increasing blastic change of bone lesions in breast and prostate cancer patients that might suggest worsening of metastases but may actually reflect healing by sclerosis [32, 33] . Other examples include benign sequelae of chemoradiation and surgery that can result in FDG avidity, such as pneumonitis, esophagitis, and osteonecrosis [34] . Diffuse increase in FDG avidity in the bone marrow and spleen is commonly seen after treatment with granulocyte colony stimulating factor, which can also mimic metastases [35] .
Our study has several limitations. It was a single institutional retrospective study, with the associated potentials for bias. Our study had some sources of heterogeneity that might be potentially confounding. For example, many of the PET/CT scans were performed at outside institutions and many patients underwent chemoradiation at outside institutions. The details of these PET/CT scans and radiation technique were unavailable to us. Our reference standard was not histological, in most cases. However, the evolution and appearance of the cases of radiation hepatitis and metastatic disease seem sufficiently distinctive that we doubt that misdiagnosis is a significant source of study error.
In conclusion, new foci of increased FDG avidity are commonly seen in the caudate and left hepatic lobes of the liver during neoadjuvant chemoradiation of distal esophageal cancer, and these findings generally reflect radiation-induced liver disease rather than metastatic disease.
